Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 1;194(11):5085-93.
doi: 10.4049/jimmunol.1403243. Epub 2015 Apr 27.

Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy

Javad Rasouli  1 , Bogoljub Ciric  1 , Jaime Imitola  1 , Patricia Gonnella  1 , Daniel Hwang  1 , Kedar Mahajan  1 , Elisabeth R Mari  1 , Farinaz Safavi  1 , Thomas P Leist  1 , Guang-Xian Zhang  1 , Abdolmohamad Rostami  2
Affiliations

Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy

Javad Rasouli et al. J Immunol. .

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the CNS. Studies in animal models of MS have shown that GM-CSF produced by T cells is necessary for the development of autoimmune CNS inflammation. This suggests that GM-CSF may have a pathogenic role in MS as well, and a clinical trial testing its blockade is ongoing. However, there have been few reports on GM-CSF production by T cells in MS. The objective of this study was to characterize GM-CSF production by T cells of MS patients and to determine the effect of IFN-β therapy on its production. GM-CSF production by peripheral blood (PB) T cells and the effects of IFN-β were characterized in samples of untreated and IFN-β-treated MS patients versus healthy subjects. GM-CSF production by T cells in MS brain lesions was analyzed by immunofluorescence. Untreated MS patients had significantly greater numbers of GM-CSF(+)CD4(+) and CD8(+) T cells in PB compared with healthy controls and IFN-β-treated MS patients. IFN-β significantly suppressed GM-CSF production by T cells in vitro. A number of CD4(+) and CD8(+) T cells in MS brain lesions expressed GM-CSF. Elevated GM-CSF production by PB T cells in MS is indicative of aberrant hyperactivation of the immune system. Given its essential role in animal models, abundant GM-CSF production at the sites of CNS inflammation suggests that GM-CSF contributes to MS pathogenesis. Our findings also reveal a potential mechanism of IFN-β therapy, namely suppression of GM-CSF production.

PubMed Disclaimer

Conflict of interest statement

POTENTIAL CONFLICT OF INTEREST

The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1. Human PB T cells express GM-CSF
PBMCs from healthy donors (n=15) were activated with PMA + ionomycin + Golgiplug (PMA/iono/GP), stained and analyzed by flow cytometry. A) Representative flow cytometry dot-plots for gated CD4+ and CD8+ T cells from one donor. B) Summary (%) for GM-CSF+ CD4+ and CD8+ T cells among total CD4+ and CD8+ T cells. C) Representative histogram for T-bet expression in GM-CSF+IFN-γ+ and GM-CSF+IFN-γ− CD4+ and CD8+ T cells from one donor (n=5). D) Representative histogram for CCR10 expression in GM-CSF+IFN-γ−, GM-CSF+IFN-γ+, GM-CSF−IFN-γ+, and GM-CSF−IFN-γ− CD45RA−CD4+ cells. Graph on the right shows the percentage of CCR10+ cells in CD45RA−CD4+ T cells (mean ± SEM, n=6).
Figure 2
Figure 2. Untreated MS patients have more GM-CSF-producing T cells than healthy individuals and IFN-β-treated MS patients
PBMCs from healthy donors (n=15), untreated MS patients (n= 15), and IFN-β-treated MS patients (n=10) were activated with PMA/iono/GP, stained and analyzed by flow cytometry. A) Collective data (%) of GM-CSF+ CD4+ and CD8+ T cells among total CD4+ and CD8+ T cells. B) IFN-γ expression by CD4+ and CD8+ T cells. C) and D) flow cytometry analysis of GM-CSF expression in IFN-γ+ and IFN-γ− T cells. * p < 0.05, ** p < 0.01, *** p < 0.001, NS: not significant, (One-way ANOVA).
Figure 3
Figure 3. IFN-β suppresses GM-CSF production by T cells from healthy donors
PBMCs and purified CD4+CD45RA− T cells from healthy donors were stimulated with anti-CD3 and anti-CD28 Abs for five days, with or without addition of IFN-β. A) Concentrations of GM-CSF, IL-10, IL-17A and IFN-γ in cell culture supernatants from PBMCs (n=15) assayed by ELISA. B) Percentages of GM-CSF+ and IFN-γ+ CD4+ and CD8+ cells in total CD4+ and CD8+ T cells from above PBMC cultures (n=15). C) To evaluate direct effect of IFN-β on CD4+ T cells, purified CD45RA−CD4+ T cells and PBMCs from the same donors (n=8) were cultured in the presence of IFN-β. Percentages of GM-CSF+, GM-CSF+IFN-γ+ and GM-CSF+IFN-γ− CD4+ cells in total CD4+ cells. GM-CSF concentrations measured by ELISA in cell culture supernatants. * p<0.05, ** p<0.01, *** p<0.001, NS: not significant (Paired, two-tailed Student t-test).
Figure 4
Figure 4. IFN-β reduces GM-CSF production by T cells from MS patients
PBMCs of IFN-β-treated and untreated MS patients were cultured with anti-CD3 and anti-CD28 Abs for five days with or without addition of IFN-β. A) GM-CSF, IL-10, IL-17A, and IFN-γ concentrations in above cell culture supernatants. B) Percentages of GM-CSF+ and IFN-γ+ CD4+ and CD8+ cells in total CD4+ and CD8+ T cells from above PBMC cultures. * p<0.05, ** p<0.01, *** p<0.001, NS: not significant (Paired, two-tailed Student t-test).
Figure 5
Figure 5. IFN-β reduces numbers of GM-CSF only CD4+ and CD8+ T cells
PBMCs from healthy donors (n=15) and MS patients (untreated MS n=13; IFN-β treated n=9) were stimulated with anti-CD3/anti-CD28 Abs in the presence or absence of IFN-β. Percentages of GM-CSF+IFN-γ+ and GM-CSF only CD4+ and CD8+ T cells in total CD4+ and CD8+ cells are shown. * p<0.05, ** p<0.01, *** p<0.001, NS: not significant (Paired, two-tailed Student t-test).
Figure 6
Figure 6. CD4+ and CD8+ T cells co-express GM-CSF and IL-17A in MS brain lesions
Serial sections from MS brain were stained with A) H&E and LFB to demonstrate the infiltration of T cells and demyelination in the MS lesion. B) CD4+ and C) CD8+ T cells were stained for GM-CSF and IL-17A and analyzed by confocal microscopy. Merged images show co-localization of GM-CSF and IL-17A in CD4+ and CD8+ T cells. Negative controls are virtually devoid of staining. Scale bars= 10μm.
Figure 7
Figure 7. CD4+ and CD8+ T cells co-express GM-CSF and INF-γ in MS brain lesions
Stained sections from three MS patients were analyzed by confocal microscopy. A) CD4+ and B) CD8+ T cells in brain lesions were stained for GM-CSF and INF-γ. Merged images show co-localization of GM-CSF and INF-γ in CD4+ and CD8+ T cells. Negative controls are virtually devoid of staining. C) Quantification of CD4+ and CD8+ T cells performed by counting average of 200 cells per group from three MS brains at 20X magnification. Scale bars = 10 μm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Correlation between COVID-19 and hepatitis B: A systematic review.
    He YF, Jiang ZG, Wu N, Bian N, Ren JL. He YF, et al. World J Gastroenterol. 2022 Dec 14;28(46):6599-6618. doi: 10.3748/wjg.v28.i46.6599. World J Gastroenterol. 2022. PMID: 36569273 Free PMC article.
  • Colony stimulating factors in the nervous system.
    Chitu V, Biundo F, Stanley ER. Chitu V, et al. Semin Immunol. 2021 Apr;54:101511. doi: 10.1016/j.smim.2021.101511. Epub 2021 Nov 4. Semin Immunol. 2021. PMID: 34743926 Free PMC article. Review.
  • Multiple sclerosis.
    Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Filippi M, et al. Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Nat Rev Dis Primers. 2018. PMID: 30410033 Review.
  • COVID-19 and liver diseases.
    Elghannam MT, Hassanien MH, Ameen YA, ELattar GM, ELRay AA, Turky EA, ELTalkawy MD. Elghannam MT, et al. Egypt Liver J. 2022;12(1):43. doi: 10.1186/s43066-022-00202-2. Epub 2022 Jul 21. Egypt Liver J. 2022. PMID: 35880136 Free PMC article. Review.
  • Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma.
    Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD. Donovan LK, et al. Nat Med. 2020 May;26(5):720-731. doi: 10.1038/s41591-020-0827-2. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341580 Free PMC article.
See all "Cited by" articles

References

    1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. The New England journal of medicine. 2006;354:942–955. - PubMed
    1. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. Journal of immunology. 2007;178:39–48. - PubMed
    1. El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2010;5:189–197. - PMC - PubMed
    1. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nature immunology. 2011;12:568–575. - PMC - PubMed
    1. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nature immunology. 2011;12:560–567. - PubMed

Publication types

Substances